1M6MYTD1Å5ÅMAKS.
Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 109,65 € (+24,60 %). Medianen er 108,78 € (+23,61 %).
| Køb |
11 |
| Behold |
3 |
| Sælg |
0 |
Nyheder Til nyhedsfeedet
Monopar names head of Medical Affairs and reports ALXN1840 presentations at liver congress
Monopar appoints Dr. Jeffrey D. Kent as of September 1, 2026, to executive vice president and head of Medical Affairs. Two abstracts on ALXN1840, the late-stage development program for the treatment of Wilson disease, were accepted for presentations at AASLD “The Liver Meeting 2026,” including an oral presentation of the phase 3 results on November 8. ALXN1840 met the primary endpoint of copper mobilization over 48 weeks in the approval-relevant phase 3 study. » Mere på de.investing.com
Virksomhedstal
| (EUR) | juni 2026 | |
|---|---|---|
| Omsætning | 0 | - |
| Bruttofortjeneste | 0 | - |
| Nettoresultat | -4,66 mio. | 123,65 % |
| EBITDA | -4,66 mio. | 123,65 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 631,48 mio. € |
Antal aktier | 6,7 mio. |
Højeste/laveste i 52 uger | 108,62 € - 40,81 € |
| Udbytte | Nej |
Beta | 1,50 |
P/E (PE Ratio) | -46,29 |
PEG (PEG Ratio) | 1,62 |
K/I (PB Ratio) | 7,07 |
P/S (PS Ratio) | 0,00 |
Virksomhedsprofil
| Navn | Monopar Therapeutics Inc |
| CEO | Chandler D. Robinson |
| Medarbejdere | 22 |
